Cymabay Therapeu Ownership
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay |
Cymabay Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Cymabay Therapeu had not issued any dividends in recent years. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. For more info on Cymabay Therapeu please contact the company at 510 293 8800 or go to https://www.cymabay.com.Cymabay Therapeu Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cymabay Therapeu insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cymabay Therapeu's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cymabay Therapeu insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Wills over six months ago Disposition of 49245 shares by Robert Wills of Cymabay Therapeu at 4.05 subject to Rule 16b-3 | ||
Paul Quinlan over six months ago Disposition of 41824 shares by Paul Quinlan of Cymabay Therapeu at 7.89 subject to Rule 16b-3 | ||
Sujal Shah over six months ago Acquisition by Sujal Shah of 14625 shares of Cymabay Therapeu at 1.06 subject to Rule 16b-3 | ||
Wiggans Thomas G over a year ago Acquisition by Wiggans Thomas G of 14010 shares of Cymabay Therapeu subject to Rule 16b-3 | ||
Stuart Lewis J over a year ago Acquisition by Stuart Lewis J of 215000 shares of Cymabay Therapeu subject to Rule 16b-3 |
Cymabay Therapeu Outstanding Bonds
Cymabay Therapeu issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cymabay Therapeu uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cymabay bonds can be classified according to their maturity, which is the date when Cymabay Therapeu has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |